Compare AbbVie Inc (ABBV) vs Nu Holdings Ltd (NU) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

NU stock trades at $13.61, showing no change in the last 24 hours. The technical outlook is bullish based on moving averages, with key support at $13 and resistance at $14. Fundamentally, the company demonstrates robust growth, with revenue increasing from $3.0B in 2022 to $10.63B in 2025 and net income turning positive to $2.87B. Recent earnings show mixed results, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026 against expectations.

The investment outlook is positive, supported by strong analyst consensus with a $14.98 price target and 55% buy ratings. Key opportunities include expansion in Latin America and a high return on equity of 30.04%. Risks involve recent earnings misses, competitive pressures, and macroeconomic volatility in emerging markets. The stock presents a growth opportunity but requires monitoring of execution and regional economic conditions.